The At its meeting in December 2022 a Extension forTadalafil (Adcirca, Eli Lilly) recommended:
The indication should be extended to the treatment of pediatric patients 2 years of age and older with pulmonary arterial hypertension, classified as WHO functional classes II and III.Until now, the indication was limited to adult patients.
This full text is unfortunately reserved for medical professionals
You have reached the maximum number of articles for unregistered visitors
Source — https://www.univadis.de/viewarticle/ema-empfiehlt-zulassungserweiterung-f%25C3%25BCr-tadalafil-2022a10028ox
Comments are closed.